News

ACADIA Pharmaceuticals Files New Drug Application for NUPLAZID In Parkinson’s Disease Psychosis

ACADIA Pharmaceuticals Inc., a biopharmaceutical company specialized in the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, has just announced it has filed for a New Drug Application with the US Food and Drug Administration for NUPLAZID (pimavanserin) for the treatment of psychosis associated…

Study Finds High Frequency of Parkinsonism in Adults With Autism

A study entitled “High rates of parkinsonism in adults with autism”, published 30 August, 2015 in the Journal of Neurodevelopmental Disorders, has established a correlation between autism and parkinsonian motor signs. Autism spectrum disorder (ASD) is diagnosed in approximately 1.5% of children in the…

Scientists Investigate Cure for Parkinson’s Disease Associated Dementia

Neuroscientists from the University of Adelaide are leading a first-of-its-kind study on a type of dementia commonly observed in patients with Parkinson’s disease, which the scientists hope lead to a potential new therapy. From September 1-7, 2015, during the Parkinson’s Awareness Week, the University of Adelaide’s School of Medicine’s Dr. Lyndsey Collins-Praino will be…

New Type of Prion May Cause And/Or Transmit Rare But Fatal Brain Disorder

According to two new research papers led by University of California at San Francisco (UCSF) scientists, Multiple System Atrophy (MSA), a progressive neurodegenerative disorder with similarities to Parkinson’s disease, is caused by a newly discovered type of prion, a variant of the misfolded proteins associated with incurable progressive brain diseases…

Dopamine-Neurons’ High Energy Requirements Leads to Neuronal Overheating in Parkinson’s Disease

In a new study entitled “Elevated mitochondrial bioenergetics and axonal arborization size are key contributors to the vulnerability of dopamine neurons” scientists discovered why dopamine producing neurons are particularly vulnerable in Parkinson’s disease. These new findings point towards a key role for mitochondria and these neurons’ high energy requirements…

Lawson Research Institute and STEMCELL Tech. Partner to Commercialize Novel Tools for Parkinson’s Disease Research

The Lawson Health Research Institute recently signed a licensing agreement with STEMCELL Technologies to transfer international exclusive rights to commercialize innovative tools for Parkinson’s Disease research. STEMCELL Technologies provides more than 2,000 products to over 70 countries worldwide, including cell culture reagents, instruments and tools designed to support science along the basic to translational…

Your Parkinson’s Community

Woman laying down illustration

Visit the Parkinson’s News Today forums to connect with others in the Parkinson’s community.

View Forums